The Hippo Signaling Pathway and Cancer

​​The Hippo signaling pathway is rapidly gaining recognition as an important player in organ size control and tumorigenesis, and many leading scientists are showing increased interest in this growing field and it's relation to cancer.  The chapters in this volume cover virtually all aspects of tumor biology, because members of the Hippo Pathway have been associated with numerous well-established cell signaling pathways, just to name a few; Ras, Wnt, TGFbeta and p53. Moreover, Hippo signaling is not solely involved in regulating “classic” tumor characteristics such as cell proliferation, survival and growth, but is also diversely involved in cell-autonomous and non-cell-autonomous differentiation, migration and organ size control. The primary audience are researchers interested in basic science in the areas of tumor suppression, cell cycle and size regulation, development and differentiation.

Dr. Moshe Oren has been investigating the molecular biology of cancer-related processes for years, with particular emphasis on the p53 tumor suppressor and its associated network of proteins and genes. Dr. Oren has cloned he p53 gene when he was a post doc working under Dr. Arnold Levine. He has acted as a member of several international research consortia, as well as co-organizer of numberous national and international conferences. Dr. Oren has won several cancer research awards and his most recent achievement includes serving as President Elect of the European Association for Cancer Research in 2010. He serves on several editorial boards including Molecular Cell, EMBO Journal, Molecular and Cellular Biology, Molecular Carcinogenesis, and Molecular Oncology, to name a few.

Dr. Yael Aylon is a research associate in Dr. Oren's lab at the Weizmann Institute and has been invited to speak at several international conferences and seminar.